Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IR-2022-002 is a functional ingredient developed by Dong-A Pharmaceutical for the mitigation of hangover symptoms. It is a fermented extract derived from rice germ and soybeans, categorized as a health functional food ingredient in South Korea. The substance functions by enhancing the metabolic breakdown of alcohol and its toxic metabolite, acetaldehyde, through the stimulation of alcohol dehydrogenase (ADH) and acetaldehyde dehydrogenase (ALDH) enzymes. By accelerating these enzymatic pathways, IR-2022-002 facilitates the rapid clearance of ethanol and acetaldehyde from the bloodstream, thereby reducing common hangover symptoms such as headaches, nausea, and fatigue. The ingredient received individual recognition from the South Korean Ministry of Food and Drug Safety (MFDS) in late 2023 and is utilized as a key active component in Dong-A's Morning Care product line.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on IR-2022-002.